Will the Cabinet Secretary confirm whether the gene-editing therapy Casgevy (exagamglogene autotemcel) is now available to eligible patients with sickle cell disease and transfusion-dependent beta thalassaemia in Wales?
Answered by Cabinet Secretary for Health and Social Care | Answered on 22/04/2025
In line with recommendations by the National Institute for Health and Care Excellence, Exagamglogene Autotemcel is available for eligible Welsh patients for both transfusion dependent beta-thalassaemia and sickle cell disease, through referral by haematology teams to designated specialised centres.